ALK and non-small cell lung carcinoma: Approximately 2–7% and1–2% of NSCLC samples show rearrangements in ALK and ROS1, respectively [5].For ALK inhibition in NSCLC, crizotinib is more effective and better toleratedthan chemotherapy [39, 40].